Cancer News

Everolimus gets FDA approval for another indication

Everolimus got approved by the FDA for the treatment of inoperable, locally advanced or metastatic neuroendocrine tumors of gastrointestinal or lung origin.

Should lung and esophageal cancer survivors do more PET scans?

Lung and esophageal cancer survivors may not get benefit from radioactive imaging tests used to diagnose cancer recurrence, a new study reveals.

Durvalumab gets FDA breakthrough status for bladder cancer

AstraZeneca‘s new drug durvalumab brings hope to bladder cancer patients receiving breakthrough therapy designation by the US FDA.

Should pancreatic cancer patients receive adjuvant chemotherapy?

Patients with resectable pancreatic cancer benefited from receiving at least 6 months of adjuvant chemotherapy, a new study suggests.

US regulators grant breakthrough therapy for AML treatment

Novartis’ investigational drug, midostaurin, received breakthrough therapy designation for US regulators for acute myeloid leukemia.

Is colonoscopy necessary to colorectal cancer after resection?

Researchers report that post-operative colonoscopy is critically important for colorectal cancer patients to avoid cancer resection.

Guidelines for active surveillance in low-risk prostate cancer

A report on active surveillance of low-risk prostate cancer patients clarifies who should undergo "active surveillance” instead of prostatectomy or radiation.

Is heart testing necessary for cancer patients on chemotherapy?

Cancer patients undergoing chemotherapy should be made aware of the increased risk of heart problems related to chemotherapy’s toxic effects.

Endometrial Cancer Surgery: comparing treatment methods

A new analysis reveals that minimally invasive hysterectomy appears to be safe for women with endometrial cancer.

Osimertinib gets EU approval for non-small cell lung cancer

EU regulators approved osimertinib for the treatment of adult patients with a specific mutation-positive non-small cell lung cancer.

Risk link identified between breast and thyroid cancer survivors

Breast or thyroid cancer survivors are more likely to develop the other type later in life compared to women with no breast or thyroid cancer history.

New therapeutic approach shows promise against multiple myeloma

A new immunotherapy-related therapeutic approach against multiple myeloma induced record-level clinical results, researchers reveal.

Are adult cancer survivors at risk of heart disease?

Adult cancer survivors are at increased risk of cardiovascular disease, a new U.S. study finds. Moreover, survivors of certain cancers face a higher risk.

Interrupting radiation therapy may lead to cancer recurrence

A new study reveals that interrupting radiation therapy during cancer treatment may lead to cancer recurrence, especially for head and neck cancers.

Childhood leukemia survivors at risk for learning problems

Pediatric acute lymphoblastic leukemia patients treated with chemotherapy alone remain at risk for attention and learning problems later, researchers report.

Carfilzomib promising for multiple myeloma

Adding carfilzomib to the treatment of relapsed and/or refractory multiple myeloma with bortezomib and lenalidomide induced positive results, a new study shows.

Proton radiotherapy gives hope to childhood brain cancer patients

Treatment with proton radiotherapy in childhood brain cancer resulted in fewer side effects and similar survival rates as conventional radiotherapy.

Breast reconstruction with fat injection: safe in breast cancer

Breast reconstruction with fat injection proved to be safe for women with recurrent breast cancer, according to a new study.

Ramucirumab: EU approval for lung and metastatic colorectal cancer

Ramucirumab received approval by the European Commission to be used as a treatment for advanced non-small cell lung cancer and metastatic colorectal cancer.

FDA approves breast cancer drug Halaven for liposarcoma

Eisai’s breast cancer drug eribulin mesylate (Halaven) received FDA’s approval to treat patients with liposarcoma.

Docetaxel to be funded by NHS England for advanced prostate cancer

Docetaxel chemotherapy will be made available to newly diagnosed advanced prostate cancer patients in England, the NHS has announced.

Why should breast cancer patients quit smoking?

One large study assessing breast cancer survivors’ smoking habits both before and after diagnosis reports that quitting smoking after diagnosis lowers risk of death.

Olaparib gets UK’s approval for ovarian cancer

UK’s regulators have recommended olaparib for adult patients with relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer.

Panitumumab shows promise in metastatic colorectal cancer

Using panitumumab with best supportive care to treat metastatic colorectal cancer patients induced positive outcomes, according to a phase 3 study.

Afatinib appears effective in lung cancer patients

Afatinib improved progression-free survival and response in non-small cell lung cancer patients with common epidermal growth factor mutations and brain metastases.

Nivolumab gets NICE recommendation for advanced skin cancer

NICE recommends nivolumab as a treatment for advanced, unresectable or metastatic melanoma.

Combination treatment approved for melanoma

US regulators approved the combination of nivolumab plus ipilimumab for the treatment of unresectable or metastatic melanoma.

Breast cancer may come back even after 24 years

A new analysis reveals that ER-positive (ER+) breast cancer may return even after more than 24 years of follow-up.

Positive outcomes from immunotherapies in gastrointestinal cancers

Pembrolizumab and nivolumab, two targeted immunotherapies, appeared effective in advanced gastric and esophageal cancers, two trials revealed.

Bladder Cancer: improved survival with adjuvant chemotherapy

Patients with locally advanced bladder cancer lived longer when treated with adjuvant chemotherapy following cystectomy, a new large study shows.

Login to your account

Did you forget your password?